Auricularia auricula polysaccharides as PD-L1 inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PD-L1 inhibitors have high adverse reaction rates and are expensive, limiting their clinical efficacy and accessibility for cancer patients.
Innovation Solution
Utilizing Auricularia auricula total polysaccharide and monomeric polysaccharide with acetyl active groups to develop PD-L1 inhibitors that can down-regulate PD-L1 expression on tumor cells, thereby inhibiting tumor growth without significant cytotoxicity or side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PD-L1 inhibitors are used, then anti-tumor efficacy is improved, but adverse reactions increase and cost increases
Solution Approach 1:
The patent replaces expensive monoclonal antibody PD-L1 inhibitors with a cost-effective polysaccharide compound derived from Auricularia auricula. The polysaccharide, characterized by specific molecular weight (10-100 kDa) and acetyl group content (15-30%), serves as a short-living, disposable alternative that achieves comparable anti-tumor efficacy without the high cost and severe adverse reactions associated with conventional inhibitors
Solution Approach 2:
The patent optimizes specific parameters of the polysaccharide compound including molecular weight (10-100 kDa), acetyl group content (15-30%), and purity (>90%) to achieve effective PD-L1 inhibition. By controlling these parameters, the polysaccharide demonstrates potent anti-tumor activity while maintaining a favorable safety profile and low production cost
2Reliability
If conventional PD-L1 inhibitors are used, then anti-tumor efficacy is improved, but production cost increases
Solution Approach 1:
The patent utilizes Auricularia auricula, an abundant and inexpensive edible fungus, as the source material for producing the polysaccharide compound. This replaces the expensive bioprocessing required for monoclonal antibody production. The polysaccharide can be extracted and purified through relatively simple steps, achieving >90% purity at low cost, making it accessible for widespread clinical use
Solution Approach 2:
The polysaccharide compound from Auricularia auricula naturally possesses the required biological activity to inhibit PD-L1 without requiring complex modification or conjugation. The compound's inherent properties (molecular weight, acetyl groups, purity) are sufficient for therapeutic effect, eliminating the need for expensive downstream processing and formulation steps required for conventional inhibitors
Data Source
AI summary
A use of Auricularia auricula total polysaccharide or monomeric polysaccharide in preparation of a PD-L1 inhibitor is provided. The Auricularia auricula total polysaccharide or monomeric polysaccharide both contain acetyl active groups. The Auricularia auricula total polysaccharide or monomeric polysaccharide containing acetyl active groups can effectively inhibit the expression of PD-L1 protein in tumor cells, inhibit the proliferation of tumor cells, and can be used as a natural PD-L1 inhibitor for the treatment of various tumors with high expression of PD-L1, such as lung cancer and colon cancer. Compared with the existing PD-L1 inhibitors, the use of Auricularia auricula total polysaccharide or monomeric polysaccharide as a PD-L1 inhibitor has the advantages of non-toxic side effects, low price, and wide adaptation to patient groups.